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Chiayi and 5) Division of Neonatology and Pediatric Hematology/Oncology, Department of Pediatrics, Chang Gung Memorial Hospital, Yunlin, TaiwanAbstractThis study aimed to identify independent predictors of clinical and microbiological treatment failure and develop a predictive model for
neonates with bloodstream infection (BSI). This study included 1087 episodes of BSIs in 793 neonates in a tertiary-level neonatal
intensive care unit of northern Taiwan between 2004 and 2012. Patient demographics, underlying chronic comorbidities, clinical features,
antimicrobial treatment and microbiological characteristics were evaluated. The presence of underlying congenital anomalies (odds ratio
[OR] 2.12, 95% conﬁdence interval [CI] 1.09 to 4.10) and pulmonary hypertension (OR 3.63, 95% CI 1.70 to 7.74), infections caused by
multidrug-resistant gram-negative bacteria (OR 2.89, 95% CI 1.23 to 6.79), group B Streptococcus (OR 3.15, 95% CI 1.33 to 7.46), and
fungi (OR 4.13, 95% CI 2.02 to 8.46), a Neonatal Therapeutic Intervention Scoring System score of  23 (OR 6.96, 95% CI 2.55 to
28.58), inappropriate antibiotics (OR 2.13, 95% CI 1.41 to 3.23), and concomitant meningitis (OR 4.25, 95% CI 2.08 to 8.69) and
ventilator-associated pneumonia (OR 2.73, 95% CI 1.22 to 6.13) were identiﬁed as independent risk factors for 28-day treatment failure
in neonatal BSI. A risk score model was created by adding the points for each independent risk factor, and had a c-statistic of 0.83.
Patients with risk scores of 0, 4, 8, 12 and 15 had estimated 28-day treatment failure rates of approximately 3.5%, 17.0%, 53.5%, 86.6%
and 95.9%, respectively. This predictive model, calculated after documentation of a BSI, reﬂects a spectrum of BSI severity and was
associated with subsequent treatment failure through illness severity score and case mix variables. This simple score could prove useful
in clinical and research settings, and practical in estimating the prognosis.
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E-mail: mingmin.tw@yahoo.com.twIntroductionNeonatal bloodstream infections (BSIs) are signiﬁcantly associ-
ated with an increased morbidity and mortality in neonatalMicrobiol Infect 2015; 21: 482.e9–482.e17
nical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2015.01.009intensive care units (NICUs) [1–3]. The reported mortality
rate of neonatal BSI ranges from 7.2% to 17.8% [2,4,5] despite
the fact that broad-spectrum antibiotics are administrated on
time. In recent years, antimicrobial-resistant bacteria have
become an increasing problem in the NICU [6–8], and are
associated with a signiﬁcantly higher risk of infectious compli-
cations and in-hospital mortality. There is also growing evi-
dence that infection with some organisms, such as methicillin-
resistant Staphylococcus aureus or Pseudomonas, with an
increased antimicrobial MIC that is still within the susceptible
range may be associated with increased rates of treatment
failure [9,10].ious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Hsu et al. Predictors of neonatal bacteraemia 482.e10Given the emerging information regarding the outcomes of
antimicrobial therapy for neonatal BSIs, a comprehensive eval-
uation of the patients, pathogens, treatment characteristics, and
underlying comorbidities is necessary to determine which fac-
tors or combinations of factors are most predictive of the
outcomes and whether any treatment strategies can improve
the outcomes. Traditionally, studies evaluating neonatal BSIs
have often focused on very low birth weight (VLBW, birth
weight  1500 g) infants [5,11–14] and lacked one or more of
the aforementioned factors. In addition, previous studies used
early mortality [11,12] or last positive blood culture before
death [13] for analysis, whereas some important outcome pa-
rameters, such as infectious complications and recurrence,
were often ignored [11–14]. The aim of the present study was
to determine the clinical and microbiological outcomes of
neonatal BSIs, identify independent predictors of treatment
failure, and develop a scoring model with which to estimate the
prognosis.Patients and methodsStudy setting, design, and population
This retrospective cohort study was conducted in the NICU of
Chang Gung Memorial Hospital, a university-afﬁliated teaching
hospital and referral centre in Northern Taiwan with an annual
admission of 1700 neonates. This NICU contains three units,
and has a total capacity of 47 beds with mechanical ventilators
and 58 beds with special nurseries. All infants < 34 to 35
weeks’ completed gestation, with a birth weight < 2 kg or >
5 kg, or with any clinical signs of respiratory distress or car-
diovascular, gastrointestinal, or neurologic problems requiring
surgical or intensive treatment were eligible for admission in
our NICU. We retrospectively screened for neonates with
BSIs hospitalized in the NICU between July 2004 and June
2012. All episodes of BSI were considered as an independent
event, but the subsequent episode of a BSI that occurred < 1
month after the previous one was excluded from the analysis.
Infants without detailed medical records and those who were
transferred to other hospitals before the outcomes could be
assessed were excluded from analysis. This study was approved
by the institutional review board of Chang Gung Memorial
Hospital, with a waiver of informed consent because all patient
records/information was anonymized and de-identiﬁed before
analysis.
Demographic characteristics were obtained from a pro-
spectively collected database in our NICU [2,6]. We reviewed
the patients’ medical records and collected detailed information
of each BSI as follows: the antimicrobial treatment data, addi-
tional interventions (surgery, invasive intubation, use of centralClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infvenous catheters or total parenteral nutrition), and response to
treatment. The severity of illness was scored using the Neonatal
Therapeutic Intervention Scoring System (NTISS) [15], with
variables taken at the ﬁrst 48 hours after onset of the BSI
episode.
Deﬁnitions
An episode of BSI was deﬁned according to clinical and
microbiological criteria, which considered any bacteria isolated
from at least one blood culture and not pertaining to the
saprophytic skin ﬂora as signiﬁcant. Growth of Corynebacterium,
Propionibacterium, Penicillium, or Diphtheroids in the blood cul-
tures was considered contaminant and excluded. For coagulase-
negative staphylococci (CoNS) BSI, the diagnosis required
clinical signs of sepsis, a blood culture positive for CoNS, and
intravenous antibacterial therapy for at least 5 days after per-
forming the blood culture, or until death [2,12,13]. Early-onset
and late-onset sepsis were deﬁned as clinical sepsis and a pos-
itive blood culture obtained within and after 3 days of life
[2,3,16], respectively.
Blood cultures were requested at the discretion of the
attending physician and processed using the Bactec 9240 cul-
ture system. Identiﬁcation of all causative microorganisms was
performed using standard microbiological methods. Antibiotic
susceptibility patterns were determined according to methods
recommended by the National Committee for Clinical Labo-
ratory Standards Institute (CLSI) for disk diffusion method, and
categorical assignment was performed using CLSI breakpoints
[17]. Extended-spectrum β-lactamase–producing gram-
negative bacteraemia and multidrug-resistant gram-negative
bacteraemia were deﬁned according to CLSI guidelines and
previous publications, respectively [6,17–19]. Polymicrobial
BSIs were deﬁned as more than 1 μg identiﬁed from a single set
of blood cultures [20]. The ﬁrst-line antibiotics in our NICU
were ampicillin plus gentamicin and oxacillin or vancomycin
plus gentamicin or cefotaxime for early-onset sepsis and late-
onset sepsis, respectively. Empirical antibiotic therapy was
considered inappropriate if the treatment regimen did not
include at least one antibiotic active in vitro against the infecting
microorganisms within 24 hours of blood culture collection.
All comorbidities of prematurity, including respiratory
distress syndrome (RDS), intraventricular haemorrhage, bron-
chopulmonary dysplasia, and necrotizing enterocolitis (NEC)
were based on the latest updated diagnostic criteria in the
standard textbook of neonatology [21]. All concurrent infec-
tious focus, including NEC, ventilator associated pneumonia
(VAP), catheter-related BSIs or meningitis were also recorded
and based on the strict diagnostic criteria of Centers for Dis-
ease Control and Prevention and previous ofﬁcial publications
[22–24].ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e9–482.e17
482.e11 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIThe 28-day mortality was deﬁned as mortality occurring in
the 28-day period after acquisition of the index blood culture.
Microbiological failure was deﬁned as growth of the causative
pathogen from a blood culture or other sterile sites (such as
cerebrospinal ﬂuid, empyema, pleural ﬂuid or ascites) at  5
days from the index culture while the patient was receiving
effective antibiotics. Focal infectious complications included
abscess, empyema, bacterial endocarditis (diagnosed by the
echocardiographic presence of visible vegetation), ventriculitis,
osteomyelitis and/or septic arthritis or other focal suppurative
processes that occurred at least 24 hours after onset of the
BSIs. Otherwise, it was considered as a concomitant infectious
focus. Recurrence of BSI was deﬁned as a new-onset clinical
sepsis and a blood culture positive for a noncontaminant
microorganism within 7 days after completion of antibiotic
therapy for the index episode of BSI. Clinical failure was deﬁned
as a composite of mortality, microbiological failure, recurrence
of BSI and occurrence of subsequent focal infectious compli-
cations within 28 days after onset of the BSI.
Statistical analysis
Differences in all characteristics between groups of favourable
outcome and treatment failure within 28 days were compared.
Categorical variables were analysed using the χ2 test or 2-sided
Fisher exact test as appropriate. Continuous variables were
analysed using the independent-sample t test or the nonpara-
metric Mann-Whitney U test. All p values were 2-tailed, and p
values <0.05 were considered to be statistically signiﬁcant. To
investigate the predictors of clinical treatment failure for
neonatal BSIs in 28 days after positive blood culture, univariate
and multivariate Cox-regression analyses were performed. All
variables with a p value <0.05 in the univariate analysis were
included in the multivariate Cox regression model.
The probability of concordance, or c-statistic, was used to
quantify the discriminative ability of the ﬁnal multivariate logistic
model. The c-statistic is equivalent to the area under a receiver-
operator characteristic curve, with a value of 0.5 denoting a
random prediction and a value of 1.0 denoting a perfect predic-
tion. To estimate the optimism bias from the model selection
process and then compute a bias-corrected c-statistic, each
bootstrap-selected model was examined on the original data, and
its performance was measured [25]. Bias was estimated as the
average difference in c-statistic values between the bootstrap
model and the test model, which was then subtracted from the
apparent concordance to obtain a bias-corrected c-statistic. To
visually assess calibration, deciles of predicted risk were plotted
from the ﬁnal multivariate logistic model by the actual fraction of
patients whose treatment failed within 28 days.
From the ﬁnal multivariate model, regression coefﬁcients
were used to derive a risk score for 28-day treatment failure.Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectPoints were assigned for the presence of each risk factor in the
ﬁnal multivariate logistic model, and weighted approximately by
the corresponding regression coefﬁcient. For each risk factor,
the regression coefﬁcient was divided by the minimum value
among all coefﬁcients in the ﬁnal multivariate model, and the
absolute value was taken. Predicted probabilities obtained
directly from the scoring model were plotted by risk score
values to visualize the estimated risk of 28-day treatment fail-
ure. All analyses were carried out using SPSS version 17.0 for
Windows (SPSS Inc., Chicago, IL, USA) and R version 3.0.2,
package Design and pROC (The R Foundation for Statistical
Computing, Vienna, Austria).ResultsDuring the study period, we identiﬁed a total of 1078 episodes
of BSI in 793 neonates from our NICU, including 68 episodes of
early-onset sepsis and 1010 episodes of late-onset sepsis
(Fig. 1). Episodes of BSI were excluded because they had
incomplete medical records (n = 8), were a recurrent episode
within 1 month after the previous one (n = 95), and had been
transferred to other hospitals (n = 5), leaving a total of 970
episodes of BSI in 777 neonates for analysis. Overall, approxi-
mately two thirds of the population were inborn (65.8%),
VLBW infants (59.7%), and had a gestational age of 30 weeks
(61.3%) (Table 1). The majority of the subjects had one episode
of BSI (79.5%), and the median age at onset of BSI was 26.0 days
(interquartile range: 15 to 51 days). Most infections (84.1%)
were primary BSIs, whereas others were combined with
certain infectious focus, including meningitis (n = 57), catheter-
related BSI (n = 53), NEC and/or peritonitis (n = 21), VAP
(n = 36), and osteomyelitis, septic arthritis or urinary tract
infection (total n = 7).
Although almost all neonates received empiric antibiotics
shortly after onset of bacteraemia, only 72.6% episodes of BSI
were treated with appropriate antibiotics within 24 hours after
the onset of bacteraemia. The rate of appropriate empirical
antibiotics was consistent throughout the study. Outcome as-
sessments at 28 days after acquisition of the index blood culture
revealed a mortality rate of 9.5% (n = 92), a microbiological
failure rate of 3.9% (n = 38), a focal infectious complication rate
of 6.9% (n = 67) and a recurrence rate of 5.7% (n = 55).
Overall, 20.3% (n = 197) had clinical failure at 28 days and the
overall in-hospital mortality rate was 14.2 % (110 of 777).
A bivariate (success vs. failure) outcome analysis was con-
ducted, evaluating the patients, pathogens, treatment modal-
ities, and underlying characteristics (Table 2 and Table 3). A low
Apgar score at 5 minutes (7), illness severity (by NTISS in the
ﬁrst 48 hours), inappropriate antibiotic therapy in the ﬁrst 24ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e9–482.e17
TABLE 1. Patient demographics and microbiological characteristics of 777 neonates with 970 episodes of BSI in the neonatal
intensive care unit
Patients demographics No. (%) (total n [ 777) Microbiological characteristics No. (%) (total n [ 970 episodes)
Birth body weight (g), median (IQR) 1350.0 (958.5–2058) Pathogens
Gestational age (wks), median (IQR) 30.0 (27.0–35.0) Early-onset sepsis 65 (6.7)
Sex (male/female) 422 (54.3)/355 (45.7) Group B streptococcus 22 (2.3)
Method of delivery (NSD/CS) 323 (41.6)/454 (58.4) E. coli 18 (1.9)
Inborn/outborn 511 (65.8)/266 (34.2) Other gram-positive pathogens 14 (1.4)
Perinatal history Other gram-negative pathogens 9 (0.9)
Low Apgar score at 5 min (7) 335 (43.1) Fungemia 2 (0.2)
Prolonged rupture of membrane (>24 h) 153 (19.7) Late-onset sepsis 905 (93.3)
Maternal fever and/or chorioamnionitis 22 (2.8) Gram-positive organisms 516 (53.2)
Perinatal asphyxia and/or HIE 28 (3.6) CONS 357 (36.8)
Underlying chronic conditions*, n (%) Staphylococcus spp. 109 (11.2)
Congenital anomalies† 44 (5.7) Enterococcus spp. 24 (2.5)
Neurological comorbidity 88 (11.3) Group B streptococcus 26 (2.7)
Cardiovascular Gram-negative organisms 302 (31.1)
Complicated congenital heart disease 34 (4.4) E. coli 74 (7.6)
Acyanotic heart disease with heart failure 18 (2.3) Klebsiella spp. 113 (11.6)
Respiratory Enterobacter spp. 41 (4.2)
Bronchopulmonary dysplasia 299 (38.5) Acinetobacter baumannii 36 (3.7)
Pulmonary hypertension requiring iNO 30 (3.9) Pseudomonas spp. 15 (1.5)
Renal‡ 22 (2.8) Serratia marcescens 11 (1.1)
Gastrointestinal Othersǁ 12 (1.2)
Congenital GI pathology 49 (6.3) Fungemia 49 (5.1)
Sequelae after operation of GI pathology§ 26 (3.3) Polymicrobial BSI 38 (3.9)
Hematologic 5 (0.6) Age at onset of late-onset sepsis 28.0 (17.0–54.0)
No. of episodes of BSI during hospitalisation (d), median (IQR)
1 618 (79.5) Sequences of BSI during hospitalisation
2 111 (14.3) First episode 769 (79.3)
> 2 48 (6.2) 2nd episode 126 (13.0)
Duration of hospitalisation, median (IQR) 63.0 (37.0–96.0) >2nd episode 75 (7.7)
Overall in-hospital mortality rate, n (%) 110/777 (14.2)
All data were expressed as number (%), unless indicated otherwise.
BSI, bloodstream infection; CONS, coagulase-negative Staphylococcus aureus; IQR, interquartile range; iNO, inhalation nitrogen oxide; GI, gastrointestinal; NSD, Natural Vaginal
Delivery; C/S, Cesearean Section; HIE, Hypoxic ischemic encephalopathy.
*Indicating the presence during the whole hospitalisation, and some patients had >1 underlying chronic complex conditions.
†Included all documented and undocumented syndrome, chromosome anomalies, genetic or metabolic disorders, but not simple cleft palate or polydactyly.
‡Including congenital nephrotic syndrome, renal failure requiring haemodialysis and immunoglobulin A nephropathy.
§Including short bowel syndrome, GI pseudo-obstruction, adhesion ileus, and chronic malnutrition.
ǁIncluding Citrobacter freundii (3), Stenotrophomonas maltophilia (3), Hafnia alvei (2), Neisseria meningitidis (2), Chryseobacterium meningoseptium (1), Flavobacterium (1) and Morganella
morganii (1).
All episodes of neonatal bloodstream infections 
(BSIs) in the NICU of CGMH between January 
1, 2004 and June 30, 2012: 
1078 episodes in 793 infants 
1010 episodes of late-onset sepsis 
in 730 neonates
1 transferred to other hospital
2 unavailable detailed records
95 recurrent episodes
6 no detailed records
4 transferred to other 
hospital
68 episodes of early-onset sepsis 
in 68 neonates
65 episodes of early-onset 
sepsis in 65 neonates
905 episodes of late-onset 
sepsis in 717 neonates
Total 970 episodes of BSIs in 777 neonates were enrolled for 
analysis (5 patients had both early and late-onset sepsis)
FIG. 1. Enrolment of all episodes of neonatal
bloodstream infections.
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TABLE 2. Univariate logistic regression model results for risk factors of 28-day treatment failure in neonates with BSIs
Variables Treatment success (n [ 773) Treatment failure (n [ 197) Odds ratio (95% CI) p Value
Gestational age (wks), median (IQR) 30.0 (27.0–34.0) 29.0 (26.0–35.0) 0.98 (0.96–1.03)† 0.824
Birth weight (g), median (IQR) 1300 (928.5–1933) 1148 (799–2413) 0.98 (0.86–1.18)‡ 0.919
Male, n (%) 414 (53.6) 100 (50.8) 0.89 (0.65–1.22) 0.483
Outborn, n (%) 256 (33.1) 71 (36.0) 1.14 (0.82–1.58) 0.439
Low Apgar score at 5 min ( 7) 317 (41.0) 101 (51.3) 1.51 (1.11–2.07) 0.010
Underlying chronic conditions*, n (%)
Congenital anomalies 40 (5.2) 28 (14.2) 3.04 (1.82–5.06) < 0.001
Neurological comorbidity 80 (10.3) 43 (21.8) 2.42 (1.61–3.64) < 0.001
Cardiovascular
Complicated congenital heart disease 29 (3.8) 6 (3.0) 0.81 (0.33–1.97) 0.636
Acyanotic heart disease with heart failure 15 (1.9) 7 (3.6) 1.86 (0.75–4.63) 0.181
Respiratory
Bronchopulmonary dysplasia 207 (26.8) 72 (36.5) 1.57 (1.13–2.19) 0.007
Pulmonary hypertension requiring iNO 15 (1.9) 27 (13.7) 8.03 (4.18–15.42) < 0.001
Renal 14 (1.8) 15 (7.6) 4.47 (2.12–9.42) < 0.001
Gastrointestinal
Congenital GI pathology 47 (6.1) 21 (10.7) 1.84 (1.07–3.16) 0.027
Sequelae after operation of GI pathology 38 (4.9) 21 (10.7) 2.31 (1.32–4.03) 0.003
Cholestasis‡ 113 (14.6) 61 (31.0) 2.62 (1.82–3.76) < 0.001
Surgery (within 1 mo before BSI) 99 (12.8) 34 (17.2) 1.43 (0.94–2.19) 0.099
Use of steroid (within 14 d before BSI) 33 (4.3) 14 (7.1) 1.72 (0.90–3.27) 0.101
Causative pathogens, n (%)
Gram-positive organisms (excluding group
B streptococcus)
447 (57.8) 62 (31.5) 1 (reference)
Group B streptococcus 30 (3.6) 18 (9.1) 2.48 (1.31–4.68) 0.005
Gram-negative organisms 249 (32.2) 80 (40.6) 1.35 (0.98–1.87) 0.069
Fungal infections 23 (3.0) 28 (14.2) 5.40 (3.04–9.61) < 0.001
Polymicrobial organisms 24 (3.1) 16 (8.1) 1.98 (1.14–3.46) 0.010
ESBL-producing gram-negative organisms 37 (4.8) 14 (7.1) 1.52 (0.81–2.87) 0.196
Pseudomonas aeruginosa 6 (0.8) 9 (4.7) 6.12 (2.15–17.41) 0.001
Multidrug-resistant gram-negative organisms 45 (5.8) 26 (13.2) 2.46 (1.38–5.06) 0.003
NTISS score at ﬁrst 48 h, n (%)
8 27 (3.5) 4 (2.0) 1 (reference)
9–15 301 (38.9) 33 (16.7) 0.74 (0.24–2.25) 0.595
16-22 383 (49.5) 86 (43.7) 1.52 (0.52–4.44) 0.449
23 62 (8.0) 74 (37.6) 8.06 (2.67–24.28) < 0.001
Appropriate antibiotics within 24 h of onset 185 (23.9) 81 (41.1) 2.13 (1.53–2.96) < 0.001
Sequences of bloodstream infection
1st episode 643 (83.2) 126 (63.9) 1 (reference)
2nd episode 88 (11.4) 38 (19.3) 2.20 (1.44–3.73) < 0.001
>2nd episode 42 (5.4) 33 (16.7) 4.01 (2.45–6.57) < 0.001
Concomitant infectious focus§
Meningitis 34 (4.4) 23 (11.7) 2.87 (1.65–5.00) < 0.001
Catheter-related bloodstream infection 45 (5.8) 8 (4.1) 0.69 (0.32–1.48) 0.334
NEC ( stage II)ǁ, peritonitis or bowel perforation 14 (1.8) 7 (3.6) 2.00 (0.80–5.02) 0.141
Ventilator associated pneumonia 21 (2.7) 15 (7.6) 2.95 (1.49–5.84) 0.002
Others¶ 6 (0.8) 1 (0.5) — —
All data are expressed as number (%), unless indicated otherwise.
BSI, bloodstream infection; ESBL, extended-spectrum beta-lactamase; CI, conﬁdence interval; IQR, interquartile range; iNO, inhalation nitrogen oxide; GI, gastrointestinal; NEC,
necrotizing enterocolitis; NTISS, Neonatal Therapeutic Intervention Scoring System.
*Indicating the presence of chronic conditions or comorbidities at onset of bloodstream infection, and some patients had >1 underlying chronic condition. Each patient with an
underlying chronic condition was compared with those without that speciﬁc condition.
†Every increased week of gestation and increment of 500 g of birth weight, respectively.
‡Indicating direct bilirubin 1.5 mg/dL or more than 50% of the total bilirubin.
§Indicating the diagnosis of an infectious focus was concurrent with onset of bacteraemia.
ǁBased on modiﬁed Bell’s staging criteria.
¶Including osteomyelitis (2), septic arthritis (2), left thigh cellulitis (1), and urinary tract infection (2).
482.e13 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIhours, episodes of bacteraemia, most underlying chronic con-
ditions, and certain pathogens were associated with a higher
rate of 28-day treatment failure. These variables were subse-
quently included in multivariate regression analysis, and inap-
propriate antibiotics, the presence of congenital anomalies and
pulmonary hypertension requiring inhalation nitrogen oxide,
severity of illness, concomitant meningitis and VAP, and in-
fections caused by fungi, multidrug-resistant gram-negative
bacilli, and group B Streptococcus (GBS) were all identiﬁed as
independent risk factors for 28-day treatment failure. In addi-
tion, both the second episode and the subsequent episodes of
bacteraemia were associated with a higher rate of 28-day
treatment failure than the ﬁrst episode (p 0.060 and < 0.001,
respectively).Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfectA multivariate logistic model that contained only variables
that were retained in the ﬁnal model had an apparent c-statistic
of 0.831. This model calibration was satisfactory, as the
observed outcomes were fairly close to the predictions (Fig. 2).
To derive a risk score for 28-day treatment failure, points were
assigned for each variable in the ﬁnal multivariable model,
weighted approximately by the corresponding regression co-
efﬁcients (Table 3). The risk score for each BSI was calculated
based on the points from the risk proﬁle, and ranged in value
from 0 to 15. Fig. 3 compares the receiver-operator charac-
teristic curves for the multivariate logistic regression and
simpliﬁed risk score models, and shows that the simpliﬁed risk
score (c-statistic of 0.831) adequately summarized the multi-
variable logistic regression model.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e9–482.e17
TABLE 3. Final multivariate logistic regression model results
for predictors of 28-day treatment failure in patients with
BSI and risk-score point allocation for each variable
Variables
Adjusted OR
(95% CI) p Value
Scoring
points
Underlying chronic conditions
Congenital anomalies 2.12 (1.09–4.10) 0.026 2
Cholestasis 1.70 (0.97–2.74) 0.053 1
Renal 1.74 (0.79–5.28) 0.142 1
Neurological comorbidities 1.31 (0.76–2.10) 0.362 1
Pulmonary hypertension 3.63 (1.70–7.74) 0.001 3
Pathogens
Multidrug-resistant organisms 2.89 (1.23–6.79) 0.015 2
Gram-negative bacteremia 1.54 (1.01–2.36) 0.047 1
Fungemia 4.13 (2.02–8.46) <0.001 3
Group B Streptococcus 3.15 (1.33–7.46) 0.009 2
NTISS score at ﬁrst 48 h
8 1 (reference) 0
9–15 1.00 (0.29–3.49) 0.998 0
16–22 1.89 (0.55–6.48) 0.309 1
23 6.96 (2.55–28.58) 0.001 5
Inappropriate antibiotics* 2.13 (1.41–3.23) <0.001 2
Sequences of BSI
1st episode 1 (reference) 0
2nd episode 1.66 (0.98–2.81) 0.060 1
>2nd episode 3.61 (1.91–6.83) <0.001 3
Concomitant infectious focus
Meningitis 4.25 (2.08–8.69) <0.001 3
Ventilator-associated
pneumonia
2.73 (1.22–6.13) 0.015 2
BSI, bloodstream infection; OR, odds ratio; CI, conﬁdence interval; NTISS, Neonatal
Therapeutic Intervention Scoring System.
*Within 24 h after the onset of bacteremia.
FIG. 2. Calibration plot of the ﬁnal multivariate logistic model for
predictors of 28-day treatment failure in neonatal bacteraemia. Note:
the observed frequency of 28-day treatment failure plotted by deciles of
predicted probability from the original (dashed-line loess curve) and
bootstrap/bias-corrected (solid-line loess curve) modelling. Perfect
calibration is represented by the Y = X line.
FIG. 3. Receiver-operator characteristic plot of the ﬁnal multivariate
logistic model and risk-score model of 28-day treatment failure for
neonatal bloodstream infections. Note: c-statistic for both the ﬁnal
multivariate logistic and risk-score models = 0.83.
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and InfFig. 4 illustrates the predicted probability of 28-day treat-
ment failure in neonates with BSIs by risk score. A higher score
corresponded to an increased risk of treatment failure, which
included mortality, requirement of continuous treatment, or
morbidities. Patients with risk scores of 0, 4, 8, 12 and 15 hadFIG. 4. Predicted probability of 28-day treatment failure in neonates
with bloodstream infections by risk score. Note: vertical lines represent
95% conﬁdence intervals.
ectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e9–482.e17
482.e15 Clinical Microbiology and Infection, Volume 21 Number 5, May 2015 CMIestimated 28-day treatment failure rates of approximately 3.5%,
17.0%, 53.5%, 86.6% and 95.9%, respectively. The estimated
rate of treatment failure increased gradually for risk scores > 5
with wider 95% CIs, reﬂecting a fewer numbers of subjects with
increased risk.DiscussionThe present study highlights the complex interaction of factors
involved in the outcome of neonatal BSIs and presents a clini-
cally useful tool for prediction of BSIs that are at high risk of
treatment failure. Because recurrence, infectious complications
and microbiological failure were highly correlated with in-
hospital mortality in the current study, it made sense to
consider them together. The predictive model was based on
variables that were independently associated with treatment
failure, including severity of illness, certain pathogens such as
multidrug-resistant gram-negative bacteria, GBS and fungemia,
appropriateness of antimicrobial therapy, certain underlying
chronic comorbidities, and concomitant meningitis and
ventilator-associated pneumonia.
A number of therapy-unrelated parameters associated with
an adverse outcome have been reported in previous publica-
tions, including VLBW or extremely preterm infants, necro-
tizing enterocolitis, concurrent infectious focus, and speciﬁc
pathogens such as fungemia, Pseudomonas sepsis, Klebsiella
sepsis or antibiotic-resistant pathogens [6,11–14,26]. Some of
these factors were not documented in this study, which is
probably related to different outcome parameters and study
subjects. This study is different from previous ones in that all
high-risk infants, from extremely preterm to term born pa-
tients, were enrolled. However, we found similar independent
risk factors of treatment failure between different subgroups
(see Supplementary Table 1). In addition, Klebsiella, Serratia, and
Acinetobacter bacteraemia were not difﬁcult to treat, which may
be because they were often antibiotic susceptible in our NICU.
Only a few studies have investigated the relationship be-
tween appropriate antibiotic therapy and treatment outcomes
[27]. We found that the timing and choice of antimicrobial
regimens inﬂuenced the model results, especially the risk of
focal infectious complications, microbiological failure and
recurrence, which is consistent with previous studies [2,6].
Although the physicians tended to use broad-spectrum antibi-
otics for cases with higher severity, the patients with multidrug-
resistant gram-negative bacteraemia and fungemia were more
likely to be treated with inappropriate antibiotics during the
ﬁrst 24 hours and were associated with recurrence and infec-
tious complications [6]. Furthermore, fungemia was indepen-
dently associated with treatment failure and overall in-hospitalClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectmortality [2,26], which highlights the importance of early sus-
picion and prompt antifungal agents to optimize outcomes.
The severity of illness was associated with an increased
mortality rate and more impaired functional status, as in other
studies [28–30]. Although various methods are now used in the
NICU to assess the severity of illness, no mathematical formula
can completely capture the complex clinical processes in a
neonate [31–33]. The NTISS has been reported to be highly
predictive for illness severity and includes all treatment char-
acteristics [15]; however, only an NTISS score of 23 could
signiﬁcantly predict an adverse outcome in this study. Addi-
tionally, the NTISS is not universally consistent even though it is
widely applied because of its dependence on treatment policies
and decisions of physicians [33], therefore adjustments of illness
severity scores with all case-mix variables are required. Because
the NTISS may have been increased in a minority of patients
who did not receive appropriate antibiotics initially, we chose
the highest severity during the ﬁrst 48 hours of BSI for our
model. This reﬂected the inﬂuence of delayed or inappropriate
antimicrobial therapy, and led to a higher predicted probability.
Concomitant meningitis and VAP were associated with a
signiﬁcantly higher risk of morbidities and recurrence. How-
ever, these issues were rarely investigated [23,24]. Although
GBS is rarely resistant to penicillin and appropriate antibiotics
were usually administered in time, GBS bacteraemia accounted
for 33.9% of all meningitis in our cohort and has the highest
possibility to cause meningitis [2,34,35], especially in preterm
neonates [35,36]. Therefore, further studies are warranted to
investigate the risk factors and route of GBS transmission,
especially for VLBW infants.
To our knowledge, this is the ﬁrst study to analyse cases of
both early- and late-onset sepsis together in an NICU [3].
Although the pathogenesis, empirical choice of antimicrobials,
and associated comorbid conditions are usually different be-
tween the ﬁrst 3 days of life and after [3,16], we found that our
proposed predictive model was applicable to both early- and
late-onset BSIs based on the calculated predicted probability.
There are some limitations in this study. Because this study
was conducted in a single tertiary-level centre, the general
validity inevitably may be limited. Because this study extended
over a relatively long period of time, some unidentiﬁed minor
changes of routines or therapeutic modalities that occurred
during these 8 years might have affected or skewed some of the
results. In addition, lack of complete strain information and two
positive blood cultures for CoNS as documentation of BSI were
the weakness of this study. However, the unselected nature of
patients from extremely preterm to term-born infants, enrol-
ment of all episodes of BSI, and extensive patient, infection and
treatment information collected and analysed are the strengths
of the study.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 482.e9–482.e17
CMI Hsu et al. Predictors of neonatal bacteraemia 482.e16ConclusionsOn the basis of our prediction model with variables including
illness severity score, antimicrobial treatment, clinical features,
and patients and microbiological characteristics, the risk of 28-
day treatment failure in neonatal BSIs can be easily estimated
with satisfactory discrimination (c-statistic 0.83). To validate
this simple prediction model as a practical bedside tool for
counselling families, making treatment decisions and follow-up
strategies in the NICU, a prospective study to assess the true
value of this risk score in both our institution and other NICUs
is warranted in the future.
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